Related Experiment Video
Updated: May 31, 2026

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice
Published on: January 12, 2024
Drug-induced glucose-6-phosphate dehydrogenase deficiency-related hemolysis risk assessment
Yang Yang1, Zuofeng Li, Peng Nan
1School of Life Science and Technology, Tongji University, 1239 SiPing Road, Shanghai 200092, PR China.
Abstract:
Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme that protects human red blood cells from premature destruction caused by oxidative damage. People suffering from G6PD deficiency would be vulnerable to various oxidative substances, such as fava beans and oxidant drugs. Until now, many institutes, organizations or domain experts have compiled low-risk or high-risk drugs collection for patients with G6PD deficiency, mainly from the case report or clinical trails. Recently, we have explored a classification system to predict drug-induced hemolytic potential. In this paper, we screen the normally used over-the-counter (OTC) drugs for "high-risk" and "low-risk" ones to G6PD deficient patients by this system.
Related Concept Videos
Drug toxicity: Idiosyncratic Reactions
Hyperglycemia
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Inborn Errors of Metabolism
Hypoglycemia and Glucagon
Hypoglycemia
